Diabetic Kidney Disease
Tóm tắt
Diabetic kidney disease develops in approximately 40% of patients who are diabetic and is the leading cause of CKD worldwide. Although ESRD may be the most recognizable consequence of diabetic kidney disease, the majority of patients actually die from cardiovascular diseases and infections before needing kidney replacement therapy. The natural history of diabetic kidney disease includes glomerular hyperfiltration, progressive albuminuria, declining GFR, and ultimately, ESRD. Metabolic changes associated with diabetes lead to glomerular hypertrophy, glomerulosclerosis, and tubulointerstitial inflammation and fibrosis. Despite current therapies, there is large residual risk of diabetic kidney disease onset and progression. Therefore, widespread innovation is urgently needed to improve health outcomes for patients with diabetic kidney disease. Achieving this goal will require characterization of new biomarkers, designing clinical trials that evaluate clinically pertinent end points, and development of therapeutic agents targeting kidney-specific disease mechanisms (
Từ khóa
Tài liệu tham khảo
Cameron, 2006, The discovery of diabetic nephropathy: From small print to centre stage, J Nephrol, 19, S75
Reutens, 2013, Epidemiology of diabetic kidney disease, Med Clin North Am, 97, 1, 10.1016/j.mcna.2012.10.001
de Boer, 2011, Temporal trends in the prevalence of diabetic kidney disease in the United States, JAMA, 305, 2532, 10.1001/jama.2011.861
Menke, 2015, Prevalence of and trends in diabetes among adults in the United States, 1988-2012, JAMA, 314, 1021, 10.1001/jama.2015.10029
Flegal, 1998, Overweight and obesity in the United States: Prevalence and trends, 1960-1994, Int J Obes Relat Metab Disord, 22, 39, 10.1038/sj.ijo.0800541
Flegal, 2016, Trends in obesity among adults in the United States, 2005 to 2014, JAMA, 315, 2284, 10.1001/jama.2016.6458
Lozano, 2012, Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2095, 10.1016/S0140-6736(12)61728-0
Jha, 2013, Chronic kidney disease: Global dimension and perspectives, Lancet, 382, 260, 10.1016/S0140-6736(13)60687-X
Afkarian, 2013, Kidney disease and increased mortality risk in type 2 diabetes, J Am Soc Nephrol, 24, 302, 10.1681/ASN.2012070718
Caramori, 2013, Renal lesions predict progression of diabetic nephropathy in type 1 diabetes, J Am Soc Nephrol, 24, 1175, 10.1681/ASN.2012070739
1995, Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial, Kidney Int, 47, 1703, 10.1038/ki.1995.236
1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6
Tonna, 2010, Metabolic memory and diabetic nephropathy: Potential role for epigenetic mechanisms, Nat Rev Nephrol, 6, 332, 10.1038/nrneph.2010.55
Nathan, 2014, The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Overview, Diabetes Care, 37, 9, 10.2337/dc13-2112
de Boer, 2011, Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes, N Engl J Med, 365, 2366, 10.1056/NEJMoa1111732
Holman, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med, 359, 1577, 10.1056/NEJMoa0806470
Bilous, 2008, Microvascular disease: What does the UKPDS tell us about diabetic nephropathy?, Diabet Med, 25, 25, 10.1111/j.1464-5491.2008.02496.x
Retnakaran, 2006, Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74, Diabetes, 55, 1832, 10.2337/db05-1620
Bakris, 2003, Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study, Arch Intern Med, 163, 1555, 10.1001/archinte.163.13.1555
Pohl, 2005, Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations, J Am Soc Nephrol, 16, 3027, 10.1681/ASN.2004110919
Fioretto, 2007, Histopathology of diabetic nephropathy, Semin Nephrol, 27, 195, 10.1016/j.semnephrol.2007.01.012
Tyagi, 2008, Thickness of glomerular and tubular basement membranes in preclinical and clinical stages of diabetic nephropathy, Indian J Nephrol, 18, 64, 10.4103/0971-4065.42336
Drummond, 2002, The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes, Diabetes, 51, 1580, 10.2337/diabetes.51.5.1580
Osterby, 2001, Renal structures in type 2 diabetic patients with elevated albumin excretion rate, APMIS, 109, 751, 10.1034/j.1600-0463.2001.d01-142.x
Saito, 1988, Mesangiolysis in diabetic glomeruli: Its role in the formation of nodular lesions, Kidney Int, 34, 389, 10.1038/ki.1988.193
Stout, 1993, Focal mesangiolysis and the pathogenesis of the Kimmelstiel-Wilson nodule, Hum Pathol, 24, 77, 10.1016/0046-8177(93)90066-P
Fioretto, 2008, The kidney in diabetes: Dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007, Diabetologia, 51, 1347, 10.1007/s00125-008-1051-7
Tervaert, 2010, Pathologic classification of diabetic nephropathy, J Am Soc Nephrol, 21, 556, 10.1681/ASN.2010010010
Mogensen, 1983, The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy, Diabetes, 32, 64, 10.2337/diab.32.2.S64
Adler, 2003, Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64), Kidney Int, 63, 225, 10.1046/j.1523-1755.2003.00712.x
Gaede, 2004, Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria, Nephrol Dial Transplant, 19, 2784, 10.1093/ndt/gfh470
Pacilli, Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMD-Annals initiative [published online ahead of print December 9, 2016], Diabetes Metab Res Rev
Afkarian, 2016, Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014, JAMA, 316, 602, 10.1001/jama.2016.10924
Klessens, 2016, An autopsy study suggests that diabetic nephropathy is underdiagnosed, Kidney Int, 90, 149, 10.1016/j.kint.2016.01.023
Thomas, 2006, Anaemia in diabetes: Is there a rationale to TREAT?, Diabetologia, 49, 1151, 10.1007/s00125-006-0215-6
Moseley, 2012, Type 2 diabetes and bone fractures, Curr Opin Endocrinol Diabetes Obes, 19, 128, 10.1097/MED.0b013e328350a6e1
Foley, 2009, Why is the mortality of dialysis patients in the United States much higher than the rest of the world?, J Am Soc Nephrol, 20, 1432, 10.1681/ASN.2009030282
Tuttle, 1992, Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes, Kidney Int, 42, 167, 10.1038/ki.1992.274
Tuttle, 1991, Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus, N Engl J Med, 324, 1626, 10.1056/NEJM199106063242304
Tuttle, 2002, Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes, Am J Physiol Renal Physiol, 282, F103, 10.1152/ajprenal.00155.2001
Grabias, 2014, The physical basis of renal fibrosis: Effects of altered hydrodynamic forces on kidney homeostasis, Am J Physiol Renal Physiol, 306, F473, 10.1152/ajprenal.00503.2013
Premaratne, 2015, The impact of hyperfiltration on the diabetic kidney, Diabetes Metab, 41, 5, 10.1016/j.diabet.2014.10.003
Tuttle, 2017, Back to the future: Glomerular hyperfiltration and the diabetic kidney, Diabetes, 66, 14, 10.2337/dbi16-0056
Heerspink, 2016, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications, Circulation, 134, 752, 10.1161/CIRCULATIONAHA.116.021887
2016, Standards of medical care in diabetes-2016: Summary of revisions, Diabetes Care, 39, S4
Tuttle, 2014, Diabetic kidney disease: A report from an ADA consensus conference, Diabetes Care, 37, 2864, 10.2337/dc14-1296
2012, KDOQI clinical practice guideline for diabetes and CKD: 2012 update, Am J Kidney Dis, 60, 850, 10.1053/j.ajkd.2012.07.005
Patel, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med, 358, 2560, 10.1056/NEJMoa0802987
Gerstein, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545, 10.1056/NEJMoa0802743
Duckworth, 2009, Glucose control and vascular complications in veterans with type 2 diabetes, N Engl J Med, 360, 129, 10.1056/NEJMoa0808431
Papademetriou, 2015, Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes, Kidney Int, 87, 649, 10.1038/ki.2014.296
Wong, 2016, Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON, Diabetes Care, 39, 694, 10.2337/dc15-2322
Ismail-Beigi, 2010, Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial, Lancet, 376, 419, 10.1016/S0140-6736(10)60576-4
James, 2014, 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8), JAMA, 311, 507, 10.1001/jama.2013.284427
Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161
Mann, 2008, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial, Lancet, 372, 547, 10.1016/S0140-6736(08)61236-2
Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med, 369, 1892, 10.1056/NEJMoa1303154
Wright, 2015, A randomized trial of intensive versus standard blood-pressure control, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939
Perkovic, 2015, Redefining blood-pressure targets--SPRINT starts the marathon, N Engl J Med, 373, 2175, 10.1056/NEJMe1513301
Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med, 362, 1575, 10.1056/NEJMoa1001286
Rocco, 2016, A SPRINT to the finish, or just the beginning? Implications of the SPRINT results for nephrologists, Kidney Int, 89, 261, 10.1016/j.kint.2015.12.024
Tuttle, 2005, The effect of ruboxistaurin on nephropathy in type 2 diabetes, Diabetes Care, 28, 2686, 10.2337/diacare.28.11.2686
Brosius, 2016, JAK inhibition in the treatment of diabetic kidney disease, Diabetologia, 59, 1624, 10.1007/s00125-016-4021-5
Navarro-González, 2015, Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PREDIAN trial, J Am Soc Nephrol, 26, 220, 10.1681/ASN.2014010012
de Zeeuw, 2014, The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy, J Am Soc Nephrol, 25, 1083, 10.1681/ASN.2013080830
Bakris, 2015, Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial, JAMA, 314, 884, 10.1001/jama.2015.10081
Pfeffer, 2015, Lixisenatide in patients with type 2 diabetes and acute coronary syndrome, N Engl J Med, 373, 2247, 10.1056/NEJMoa1509225
Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med, 375, 311, 10.1056/NEJMoa1603827
Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 375, 1834, 10.1056/NEJMoa1607141
Zinman, 2015, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 373, 2117, 10.1056/NEJMoa1504720
Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 323, 10.1056/NEJMoa1515920
Gregg, 2014, Changes in diabetes-related complications in the United States, 1990-2010, N Engl J Med, 370, 1514, 10.1056/NEJMoa1310799
Maahs, 2013, Uric acid lowering to prevent kidney function loss in diabetes: The preventing early renal function loss (PERL) allopurinol study, Curr Diab Rep, 13, 550, 10.1007/s11892-013-0381-0
Bakris, 2015, Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial, JAMA, 314, 884, 10.1001/jama.2015.10081